Harnessing the Immune System Against Multiple Myeloma: Challenges and Opportunities von Yamamoto, Leona, Amodio, Nicola, Gulla, Annamaria, Anderson, Kenneth Carl

Volltext

Nicotinamide-Expanded Allogeneic Natural Killer Cells with CD38 Deletion, Expressing an Enhanced CD38 Chimeric Antigen Receptor, Target Multiple Myeloma Cells von Edri, Avishay, Ben-Haim, Nimrod, Hailu, Astar, Brycman, Nurit, Berhani-Zipori, Orit, Rifman, Julia, Cohen, Sherri, Yackoubov, Dima, Rosenberg, Michael, Simantov, Ronit, Teru, Hideshima, Kurata, Keiji, Anderson, Kenneth Carl, Hendel, Ayal, Pato, Aviad, Geffen, Yona

Volltext

Transcriptome Analysis of Diffuse Large B-Cell Lymphoma Cells Inducibly Expressing MyD88 L265P Mutation Identifies Upregulated CD44, LGALS3, NFKBIZ, and BATF as Downstream Targets... von Turi, Marcello, Anilkumar Sithara, Anjana, Hofmanová, Lucie, Žihala, David, Radhakrishnan, Dhwani, Vdovin, Alexander, Knápková, Sofija, Ševčíková, Tereza, Chyra, Zuzana, Jelínek, Tomáš, Šimíček, Michal, Gullà, Annamaria, Anderson, Kenneth Carl, Hájek, Roman, Hrdinka, Matouš

Volltext

Promises and Challenges of Immunogenic Chemotherapy in Multiple Myeloma von Johnstone, Megan, Vinaixa, Delaney, Turi, Marcello, Morelli, Eugenio, Anderson, Kenneth Carl, Gulla, Annamaria

Volltext

Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells von ROCCARO, Aldo Maria, HIDESHIMA, Teru, DAMMACCO, Franco, RICHARDSON, Paul Gerard, ANDERSON, Kenneth Carl, RAJE, Noopur, KUMAR, Shaji, ISHITSUKA, Kenji, YASUI, Hiroshi, SHIRAISHI, Norihiko, RIBATTI, Domenico, NICO, Beatrice, VACCA, Angelo

Volltext

Development of B-cell maturation antigen (BCMA)-specific CD8 + cytotoxic T lymphocytes using induced pluripotent stem cell technology for multiple myeloma von Bae, Jooeun, Kitayama, Shuichi, Herbert, Zach, Daheron, Laurence, Munshi, Nikhil C., Kaneko, Shin, Ritz, Jerome, Anderson, Kenneth Carl

Volltext

Enhanced CD138 peptide-specific cytotoxic T lymphocyte activities against breast, colon and pancreatic cancers in combination with pembrolizumab (anti-PD1) von Bae, Jooeun, Hideshima, Teru, Tai, Yu-Tzu, Munshi, Nikhil C., Anderson, Kenneth Carl

Volltext

Abstract 5352: Genome-wide CRISPR-cas9 screening identifies KDM6A as a modulator of CD38 expression in multiple myeloma: Therapeutic implications von Liu, Jiye, Xing, Lijie, Hideshima, Teru, Anderson, Kenneth Carl

Volltext

Investigation into aberrant B cell repertoire in myeloma on humoral immunity and patient survival von Potluri, Lakshmi Bhavani, Seah, Hannah, Bade, Vaishnavi Reddy, Krogman, Arthur, Acharya, Shree, Negroiu, Andreea Mihaela, Talluri, Srikanth, Vempati, Lakshmi Manasa, Iragavarapu, Pradyumna, Lee, Saem, Fulciniti, Mariateresa, Samur, Mehmet Kemal, Richardson, Paul G., Moreau, Philippe, Avet-Loiseau, Herve, Anderson, Kenneth Carl, Prabhala, Rao H., Munshi, Nikhil C.

Volltext

Biological correlates to support a clinical role for tagraxofusp, a novel targeted therapy directed to CD123, in combination with pomalidomide and dexamethasone, to target plasmacy... von Chauhan, Dharminder, Ray, Arghya, Song, Yan, Olguin, Arturo, Chen, Janice, Brooks, Christopher, Mughal, Tariq I., Richardson, Paul G., Anderson, Kenneth Carl

Volltext

Lenalidomide, bortezomib, and dexamethasone (RVd) ± autologous stem cell transplantation (ASCT) and R maintenance to progression for newly diagnosed multiple myeloma (NDMM): The ph... von Richardson, Paul G., Jacobus, Susanna J., Weller, Edie, Hassoun, Hani, Lonial, Sagar, Raje, Noopur S., Medvedova, Eva, McCarthy, Philip L., Libby, Edward N., Voorhees, Peter M., Orlowski, Robert Z., Anderson, Larry D., Hurd, David D., Pasquini, Marcelo C., Masone, Kelly, Moreau, Philippe, Avet-Loiseau, Herve, Attal, Michel, Anderson, Kenneth Carl, Munshi, Nikhil C.

Volltext

Abstract 141: Targeting protein secretion as a novel therapeutic strategy in AL amyloidosis von Moscvin, Maria, Czarnecki, Peter Gregor, Chen, Tianzeng, Gullá, Annamaria, Anderson, Kenneth Carl, Bianchi, Giada

Volltext

Perceptions of prognosis in caregivers of multiple myeloma (MM) patients von Shapiro, Yael N., Nadeem, Omar, Yee, Andrew Jenho, Laubach, Jacob, Branagan, Andrew R., Anderson, Kenneth Carl, Mo, Clifton C., Munshi, Nikhil C., Ghobrial, Irene M., Sperling, Adam Samuel, Mesa, Michelle M., Burke, Jill N., Harrington, Cynthia C., Agyemang, Emerentia A., Packer, Lisette R., Richardson, Paul G., Raje, Noopur S., El-Jawahri, Areej, O'Donnell, Elizabeth

Volltext

Updates from ICARIA-MM, a phase 3 study of isatuximab (Isa) plus pomalidomide and low-dose dexamethasone (Pd) versus Pd in relapsed and refractory multiple myeloma (RRMM) von Richardson, Paul G., Perrot, Aurore, F. San-Miguel, Jesús, Beksac, Meral, Spicka, Ivan, Leleu, Xavier, Schjesvold, Fredrik, Moreau, Philippe, Dimopoulos, Meletios A., Huang, Jeffrey SY, Minarik, Jiri, Cavo, Michele, Prince, H. Miles, Zheng, Cheng, Dubin, Franck, Van De Velde, Helgi, Anderson, Kenneth Carl

Volltext

Function and expression of checkpoint inhibitors and immune agonists on immune cells in monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM)... von Bae, Jooeun, Nguyen, Brandon, Tai, Yu-Tzu, Hideshima, Teru, Chauhan, Dharminder, Munshi, Nikhil C., Anderson, Kenneth Carl

Volltext

Final results of a phase Ib study of isatuximab (ISA) plus pomalidomide (Pom) and dexamethasone (dex) in relapsed/refractory multiple myeloma (RRMM) von Mikhael, Joseph, Richardson, Paul G., Usmani, Saad Zafar, Raje, Noopur S., Bensinger, William, Dubin, Franck, Liu, Qianying, Vitse, Olivier, Anderson, Kenneth Carl

Volltext

A phase III, randomized, open-label study of isatuximab (SAR650984) plus pomalidomide (Pom) and dexamethasone (Dex) versus Pom and Dex in relapsed/refractory multiple myeloma von Richardson, Paul G., Attal, Michel, San Miguel, Jesus, Campana, Frank, Le-Guennec, Solenn, Hui, Ai-Min, Risse, Marie-Laure, Anderson, Kenneth Carl

Volltext

HDAC3 regulates DNMT1 expression in multiple myeloma: therapeutic implications von Harada, Takeshi, Ohguchi, Hiroto, Grondin, Yohann Renald, Kikuchi, Shannon Adele, Sagawa, Morihiko, Tai, Y-T, Mazitschek, Ralph, Hideshima, Teru, Anderson, Kenneth Carl

Volltext

A phase III randomized, open label, multicenter study comparing isatuximab, pomalidomide, and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with... von Richardson, Paul G., Attal, Michel, Rajkumar, S. Vincent, San Miguel, Jesus, Beksac, Meral, Spicka, Ivan, Leleu, Xavier, Schjesvold, Fredrik, Moreau, Philippe, Dimopoulos, Meletios A., Huang, Jeffrey SY, Minarik, Jiri, Cavo, Michele, Prince, H. Miles, Macé, Sandrine, Corzo, Kathryn Penkus, Campana, Frank, Le-Guennec, Solenn, Dubin, Franck, Anderson, Kenneth Carl

Volltext

The myeloma-developing regimens using genomics (MyDRUG) master protocol von Auclair, Daniel, Anderson, Kenneth Carl, Avigan, David, Bianchi, Giada, Biran, Noa, Chaudhry, Maria, Cho, Hearn J., Furlong, Maggie, Hofmeister, Craig C., Kansagra, Ankit J., Krishnan, Amrita Y., Larsen, Jeremy Todd, Orloff, Gregory Joshua, Vij, Ravi, Voorhees, Peter Michael, Yee, Andrew Jenho, Ye, Jing Christine, Zonder, Jeffrey A., Lonial, Sagar, Kumar, Shaji

Volltext